Bioptix Inc  

(Public, NASDAQ:BIOP)   Watch this stock  
Find more results for NASDAQ:APPY
-0.01 (-0.28%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.48 - 3.69
52 week 2.14 - 5.92
Open 3.48
Vol / Avg. 29,445.00/17,487.00
Mkt cap 19.53M
P/E     -
Div/yield     -
EPS -1.37
Shares 5.41M
Beta 2.67
Inst. own 3%

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -45359.23%
Operating margin - -66954.67%
EBITD margin - -58734.61%
Return on average assets -26.60% -22.55%
Return on average equity -30.68% -27.57%
Employees 7 -
CDP Score - -


834 S Perry St Ste 443
CASTLE ROCK, CO 80104-1941
United States - Map
+1-303-7942000 (Phone)
+1-303-7988332 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Bioptix, Inc., formerly Venaxis, Inc., provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company's line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered. Its technology is an ultra-sensitive detection platform. The design of its SPR spectrometers allows discrete areas within the sample cell to be interrogated simultaneously by use of photo-diode arrays aligned to the reflected beam from the sample cell. Its biosensors provide information on kinetic processes (association and dissociation), binding affinities, analyte concentrations and real-time molecule detection. The Company offers 404pi Enhanced SPR System, which enables real-time detection of biomolecular interactions.

Officers and directors

Michael M. Beeghley Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
Jeffrey G. McGonegal Chief Financial Officer, Corporate Secretary
Age: 64
Bio & Compensation  - Reuters
Mike Dai Independent Director
Bio & Compensation  - Reuters
Daryl Jay Faulkner Independent Director
Age: 66
Bio & Compensation  - Reuters
Andrew E. Kaplan Independent Director
Age: 50
Bio & Compensation  - Reuters
John O'Rourke Independent Director
Bio & Compensation  - Reuters
Stephen Alaric Williams M.D. Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters